Associated Banc Corp Sells 14,083 Shares of Bristol-Myers Squibb (NYSE:BMY)

Associated Banc Corp reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 148,784 shares of the biopharmaceutical company’s stock after selling 14,083 shares during the quarter. Associated Banc Corp’s holdings in Bristol-Myers Squibb were worth $7,698,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in BMY. Horizon Kinetics Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 31.9% during the third quarter. Horizon Kinetics Asset Management LLC now owns 59,382 shares of the biopharmaceutical company’s stock worth $3,072,000 after buying an additional 14,364 shares during the last quarter. Hancock Whitney Corp raised its position in shares of Bristol-Myers Squibb by 1,213.3% during the 3rd quarter. Hancock Whitney Corp now owns 319,008 shares of the biopharmaceutical company’s stock valued at $16,505,000 after acquiring an additional 294,717 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Bristol-Myers Squibb by 29.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 277,599 shares of the biopharmaceutical company’s stock valued at $14,363,000 after purchasing an additional 62,602 shares during the period. Independent Advisor Alliance boosted its position in shares of Bristol-Myers Squibb by 3.8% in the 3rd quarter. Independent Advisor Alliance now owns 45,719 shares of the biopharmaceutical company’s stock worth $2,366,000 after purchasing an additional 1,654 shares during the last quarter. Finally, Concentric Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb by 7.1% during the third quarter. Concentric Wealth Management LLC now owns 54,695 shares of the biopharmaceutical company’s stock worth $2,830,000 after purchasing an additional 3,605 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 1.3 %

NYSE BMY traded up $0.74 during trading hours on Monday, hitting $59.61. 402,954 shares of the company traded hands, compared to its average volume of 14,303,340. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The business’s 50-day moving average is $53.66 and its 200-day moving average is $47.77. The stock has a market capitalization of $120.90 billion, a price-to-earnings ratio of -16.49, a P/E/G ratio of 15.79 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.00 EPS. Sell-side analysts anticipate that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.03%. Bristol-Myers Squibb’s dividend payout ratio is presently -66.85%.

Analysts Set New Price Targets

A number of brokerages have issued reports on BMY. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. TD Cowen lifted their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group upped their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Morgan Stanley boosted their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Finally, Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $54.07.

Insider Activity

In other news, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.